MedTrace Logo

Oscillating Positive Expiratory Pressure Therapy Versus Autogenic Drainage in Patients With COPD

NCT07402850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-02-11

No results posted yet for this study

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a long-term lung condition that causes breathing difficulty, cough, and sputum production. Airway clearance techniques are commonly used to help reduce symptoms and improve breathing in patients with COPD.

This study compared two airway clearance methods-oscillating positive expiratory pressure (OPEP) therapy and autogenic drainage-to determine which method is more effective in improving lung function, sputum clearance, shortness of breath, and quality of life in patients with COPD.

Participants were divided into two groups and received either OPEP therapy or autogenic drainage for four weeks. Outcomes were measured at the beginning of the study and again after completion of the intervention. The findings of this study aim to support evidence-based physiotherapy management for patients with COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Airway Clearance

Interventions

DEVICE

Oscillating Positive Expiratory Pressure Therapy

Oscillating positive expiratory pressure therapy was administered using a handheld device to facilitate airway clearance by providing expiratory resistance and oscillations during exhalation. The intervention was applied for four weeks.

BEHAVIORAL

Autogenic Drainage

Autogenic drainage is a breathing technique involving controlled breathing at different lung volumes to mobilize and clear bronchial secretions. Participants performed autogenic drainage sessions for four weeks.

Sponsors & Collaborators

  • Adnan Hashim

    lead OTHER

Principal Investigators

  • Adnan Hashim, DPT · Department of Physical Therapy, The University of Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2025-08-08
Completion
2025-09-12

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402850 on ClinicalTrials.gov